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Abstract
Background: Mesenchymal stromal cells (MSCs) are considered an important therapeutic tool in cancer therapy.
They possess intrinsic therapeutic potential and can also be in vitro manipulated and engineered to produce
therapeutic molecules that can be delivered to the site of diseases, through their capacity to home pathological
tissues. We have recently demonstrated that MSCs, upon in vitro priming with anti-cancer drug, become
drug-releasing mesenchymal cells (Dr-MCs) able to strongly inhibit cancer cells growth.
Methods: Murine mesenchymal stromal cells were loaded with Paclitaxel (Dr-MCsPTX) according to a standardized
procedure and their ability to inhibit the growth of a murine B16 melanoma was verified by in vitro assays. The
anti-metastatic activity of Dr-MCsPTX was then studied in mice injected i.v. with B16 melanoma cells that produced
lung metastatic nodules. Lung nodules were counted under a dissecting stereomicroscope and metastasis
investigated by histological analysis.
Results: We found that three i.v. injections of Dr-MCsPTX on day 5, 10 and 15 after tumor injection almost completely
abolished B16 lung metastasis. Dr-MCsPTX arrested into lung by interacting with endothelium and migrate toward
cancer nodule through a complex mechanism involving primarily mouse lung stromal cells (mL-StCs) and SDF-1/
CXCR4/CXCR7 axis.
Conclusions: Our results show for the first time that Dr-MCsPTX are very effective to inhibit lung metastasis formation.
Actually, a cure for lung metastasis in humans is mostly unlikely and we do not know whether a therapy combining
engineered MSCs and Dr-MCs may work synergistically. However, we think that our approach using Dr-MCs loaded
with PTX may represent a new valid and additive therapeutic tool to fight lung metastases and, perhaps, primary lung
cancers in human.
Keywords: Mesenchymal stromal cells, Lung metastasis, Paclitaxel, SDF-1, B16 melanoma, Drug-delivery
* Correspondence: leonetti@ifo.it
†Equal contributors
1Department of Biomedical, Surgical and Dental Sciences, University of Milan,
Via Pascal 36, Milan 20133, Italy
Full list of author information is available at the end of the article
© 2015 Pessina et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pessina et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:82 
DOI 10.1186/s13046-015-0200-3
Background
Adult mesenchymal stromal cells (MSCs) are a suitable
cell source for cell-based therapies [1]. MSCs possess in-
trinsic therapeutic potential [2], however, they can be in
vitro manipulated and engineered to produce therapeutic
molecules [3–6] that can be delivered to the site of dis-
ease, through their capacity to home pathological tissues
[7–9].
Despite the molecular mechanisms involved in
MSCs homing, the number of cells that reach a dis-
ease area may depend on the route of their adminis-
tration [10, 11]. After intravenous (i.v) injection most
of the cells remain trapped in draining organs such
as lung, kidney and liver [12] and this may drastically
limit the number of MSCs that can reach pathological
area in other organs. However, lung, besides its drain-
ing capacity, has been shown a promise tissue target
for cell-based therapies [13, 14].
Previous data from our group have shown that
MSCs can acquire strong anti-cancer activity upon in
vitro exposure to very high dose of chemotherapeutic
agent such as Paclitaxel (PTX). In particular, we have
shown that in vivo the co-injection as well as the
intra-tumor injection of MSCs loaded with PTX
strong inhibit tumor growth [15, 16]. MSCs become
drug-releasing mesenchymal cells (Dr-MCs) because
they are able to uptake and release the drug and thus
kill tumor cells when located nearby. This property
seems present not only in MSCs derived from bone
marrow (BM) but also in those derived from adipose
tissue [17] or in fibroblasts [18] and even in mono-
cytes [19].
In order to expand our previous work, we here investi-
gated the capacity of Dr-MCs loaded with PTX to inhibit
lung metastasis induced by i.v. injection of B16 melan-
oma cells in syngeneic C57Bl6 mice. The Dr-MCs here
used were the syngeneic SR4987 a MSC line developed
from BM of BDF/1 mice [20]. We found that SR4987
loaded with PTX (SR4987PTX) i.v. injected after tumor
cells administration, abolished almost all lung metastasis.
We demonstrated that SR4987PTX once in lung, accumu-
late nearby metastatic foci through a complex mechanism
involving resident mouse lung stromal cells (mL-StCs),
Stromal-Derived Factor 1 (SDF-1) and its receptors
CXCR4/CXCR7. We propose to use Dr-MCs loaded with
PTX as new therapeutic approach for lung metastasis.
Materials and methods
Cells
The murine melanoma cell line B16 [21] and MOLT-4
(human acute T-lymphoblastic leukemia) [22] were pro-
vided by Centro Substrati Cellulari, ISZLER (Brescia,
Italy). B16 cells were maintained in RPMI 1640 medium
(Euroclone, UK) supplemented with 10 % fetal bovine
serum (FBS) (LONZA Walkersville MD USA). MOLT-4
cells were cultured in complete IMDM +10 % FBS.
The Mesenchymal stromal cell line SR4987 was estab-
lished from a long-term BM-derived cell culture of
BDF/1 mice (ATCC CRL-2028) [23]. SR4987 cells
were cultured in IMDM supplemented with 5 % FBS.
SR4987 are positive for stem cell marker Vimentin,
CD44+, CD73+, CD105+, CD106+, Sca-1+, CD34+,
and CD45+ and have the capacity to differentiate into
osteoblasts and chondrocytes [23]. SR4987 cells were
also transduced with green fluorescent protein (GFP)
using lentiviral vector ( pCCLsin.PPThPGK.GFPpre)
as previously described [15].
Human lung-derived microvascular endothelial cells
(L-MECs) were obtained from Dr. Arnaldo Caruso (La-
boratory of Microbiology, University of Brescia, Brescia,
Italy). L-MECs were routinely maintained in endothelial
basal growth medium (EBM-GM) (EGM bullet kit,
LONZA Walkersville MD USA) on Collagen + Fibronec-
tin coated T25 flasks.
Mouse lung stromal cells (mL-StCs) were freshly iso-
lated from C57Bl6 mice by using 0.25 % collagenase D
(Boehringer Mannheim Germany). The adherent mL-
StCs were cultured in IMDM +5 % FBS and analyzed for
mesenchymal markers CD44, CD29 and CD90 (all pur-
chased from Abcam Cambridge UK, mouse MSCs panel)
to confirm their mesenchymal origin.
PTX priming of SR4987 cells
PTX was purchased from Adipogen (Vinci-Biochem,
Italy). The activity of PTX on SR4987 cells was deter-
mined in a 24 h (cytotoxicity test) and in a 7 day
MTT assay (anti-proliferative test) as previously described
[24]. Priming of SR4987 with PTX (SR4987PTX) was
carried out using PTX at 2,000 ng/ml as previously
described [15].
In vitro antitumor assay
The effect of conditioned medium (CM) from
SR4987 and SR4987PTX cells on B16 proliferation
was evaluated by MTT assay [24]. The inhibitory
concentrations (IC50 and IC90) were determined ac-
cording to the Reed and Muench formula [25]. The
antitumor activity of CM from SR4987PTX cells was
compared to that of pure PTX and expressed as
PTX equivalent concentration (PEC) [15]. The PTX
released by a single cells was calculated dividing
PEC for the number of cells seeded and expressed as
pg/cell. To establish the optimal dose of SR4987PTX
to inject, co-cultures with B16 cells were made by
using transwell inserts (0.4 μm pore size) (Becton
Dickinson, USA) [15, 16].
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Rosette adherence assay and Transmission electron
microscopy (TEM) analysis
To study the interaction between B16 cells and SR4987,
a rosette test was performed [16]. B16 were mixed in a
conical tube with SR4987 or SR4987PTX cells, in 500 μl
of IMDM+ 5 % FBS (ratio B16/SR4987 5:1). After 24 h
of incubation at 37 °C in air + 5 % CO2, 20 μl of cells
were collected by a micropipette and then transferred on
a slide to evaluate rosette formation under an inverted
microscope. Rosette were then analyzed by TEM as pre-
viously described [16].
Adhesion assay
Adhesion of SR4987 and SR4987PTX to L-MECs and
to mL-StCs were performed following a previously de-
scribed procedure [16]. L-MECs and mL-StCs mono-
layers were stimulated by adding B16 derived CM
(B16-CM), tumor necrosis factor-alpha (TNFα; 10 ng/ml;
Sigma Chemical) and their combination for 24 h. L-MECs
and mL-StCs were allowed to interact for 30’ with SR4987
and SR4987PTX (104 cells/well) in IMDM +0.2 % BSA.
Each test was run in quadruplicate (see Additional file 1).
Migration assay
Transwell supports were used to test spontaneous migra-
tion and chemotaxis of SR4987 and SR4987PTX. Migra-
tion assay was performed as previously described [26].
Test samples consisting in: mouse SDF-1 (1-100 ng/ml)
(R&D system), TNFα (1-50 ng/ml), B16-CM (1:1-1:100 di-
lutions) mL-StCs-CM (1:1-1:100 dilutions), CM derived
from mL-StCs primed for 24 h either with B16-CM (1:1)
(mL-StCs-B16-CM), TNFα 10 ng/ml (mL-StCs-TNFα-
CM) or B16-CM+TNFα (mL-StCs-B16-TNFα-CM), were
placed in the lower compartment. The blocking effect of
monoclonal antibodies (mAbs) anti mouse SDF-1 (R & D
System), as well control mouse IgG, (0.01-1ug/ml) was
tested by adding mAbs to medium containg SDF-1 or to
CMs. To block SDF-1 receptors CXCR4/CXCR7, SR4987
and SR4987PTX (5×105) were pre-incubated for 1 h at
37 °C in IMDM+ 0.2 % BSA in presence of different con-
centration of AMD3100 (0.1-10 μM) (purchased from
Sigma). Each determination was done in duplicate (see
Additional file 1).
Immunoassay for mouse SDF-1
CM samples recovered from 48 h cultured SR4987,
SR4987PTX, B16 cells, or from mL-StCs stimulated or
not with B16-CM, TNFα and B16-CM+ TNFα were an-
alyzed for the presence of SDF-1 using an Elisa kit (R&D
System). The value of SDF-1 detected in the CM were
normalized for the same number of cells counted at the
end of incubation.
Flow Cytometry and PCR
The expression of Sca-1, CXCR4 and CXCR7 on SR4987
was determind by flow cytometry (FC) using the follow-
ing antibodies: anti-Sca-1 FITC, anti-CXCR4 (ab1670)
and anti-CXCR7 (all purchased from Abcam Cambridge
UK). 20,000 events were acquired for each analysis using
Epics “XL-MLC” (Beckman Coulter, USA) and histo-
gram elaboration was performed with EXPO 32
software.
For the analysis of mRNA levels 1000 ng of total RNA
isolated using the RNeasy kit (Qiagen) was reverse-
transcribed using iScript cDNA Synthesis Kit (Bio-Rad
Laboratories). Triplicate polymerase chain reactions were
carried out on an CFX 96 Touch Real Time PCR Detec-
tion System (Bio-Rad Laboratories). Relative gene expres-
sion was calculated by a comparative method (2-ΔΔCt)
using GAPDH as an housekeeping gene. Primers se-
quences were designed using Primer3 software.
In vivo experiments and Immunohistochemistry
Six-to eight-week old male C57BL/6 mice were pur-
chased from Charles River (Calco, Milan, Italy). All
the animal experiments were performed at the Ani-
mal Facility of Regina Elena National Cancer Insti-
tute in Rome Italy following directive 2010/63/EU.
Healthy mice (2 each group) receiving i.v. injection
of saline, 106 SR4987GFP and 106 SR4987GFP-PTX.
Fluorescent cells were used to confirm their capacity
to arrest into the lung. Mice were sacrificed at 6 h,
24 h and 48 h after treatments and lungs were
minced and digested by collagenase (for 2 h at 37 °C) to
obtain a cell suspension that was rapidly analyzed under
Fluorescent microscopy. To study the anti-metastatic ac-
tivity of SR4987PTX, mice were injected i.v. with 2.5 × 105
B16 melanoma cells /0.2 ml. On day 5, after B16 injection,
mice (12 each group) were treated i.v. with 0.2 ml saline
(controls), PTX 10 mg/Kg, SR4987 (105/0.2 ml) and
SR4987PTX at 105 and 5×104/0.2 ml. Treatments were re-
peated on day 10 and 15. On day 21 after B16 injection,
mice were euthanized, lungs removed and fixed in Bouin’s
solution. Lung nodules were counted under a dissecting
stereomicroscope. Metastasis were also investigated by
histology using Hematoxylin and Eosin (HE) and by
Fontana-Masson staining to detect micrometastasis [26].
To investigate the capacity of SR4987 and SR4987PTX to
home lung B16 nodules, mice (3 each group) were
injected i.v. with 106 B16 cells. Upon 14 days mice
were i.v. treated with saline (controls), PTX (10 mg/
kg), SR4987 (105) and SR4987PTX (105) and sacri-
ficed 48 h after treatments. The lungs were processed
by immunohistochemistry for Sca-1 + cells detection
by using rabbit monoclonal anti-Sca1/Ly6A/E anti-
body (1:150, Abcam) and polyclonal anti-SDF-1
(Santa Cruz Biotechnology Inc USA) for SDF-1
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expression according to standard protocols [26, 27].
The number of Sca-1+cells was evaluated at high
power field (HPF), 400X magnification. At least 10
fields for each case were randomly evaluated with vari-
ability less than 5 %.
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). Differences between mean values were evaluated
according to Student’s t-test performed by GRAPHPA-
DINSTAT program (GraphPad Software Inc., San Diego,
CA, USA). p values < 0.05 were considered statistically
significant.
Results
SR4987 localized in the lung after i.v. injection
In preliminary experiments we verified if mouse SR4987
and SR4987PTX cells localized in the lung after i.v injec-
tion. At this purpose, GFP transfected SR4987 cells
(SR4987GFP) were prepared [15]. At 6 h, 24 h, and 48 h
following cells injection, mice were sacrificed and lungs
analyzed for the presence of SR4987GFP. Both groups of
mice treated with cells retained in the lung significant
amount of GFP+ cells until 48 h upon injection. Maximal
presence of cells was observed between 6 and 24 h. The
viability of the GFP+ cells arrested in lungs was confirmed
by culturing the cells obtained after lungs digestion. The
presence of injected cells in the lung were also ascertained
by evaluating Sca-1, a marker that is considered specific
for murine MSCs [28] and highly expressed on SR4987
(Additional file 2: Figure S2A). A significant presence of
Sca-1+ cells in both SR4987 and SR4987PTX treated mice
were found, while rare Sca-1+ cells were detected in un-
treated mice (Additional file 2: Figure S2B) by indicating
that physiological Sca-1 positive cells with bone marrow
origin is rarely seen.
SR4987PTX bind B16 melanoma cells and inhibit their in
vitro proliferation
In previous studies we have shown that SR4987 cells be-
haved as Dr-MCs since are very resistant to PTX cytotox-
icity and able to uptake/release the drug [15, 16]. The
quantification of PTX released by SR4987PTX was per-
formed by testing the anti-proliferative activity of CM
(SR4987PTX-CM) on MOLT-4, a leukemia cell line very
sensitive to PTX [29]. SR4987PTX release around 0.34 ±
0.01 pg and incorporate around 2.5 ± 0.05 pg of PTX/cell
in 24 h [15]. We found that SR4987PTX-CM inhibited B16
proliferation in a dose-dependent manner, with an IC50 at
dilution 1/9.98 ± 2.4 corresponding at 7.18 ± 4.99 ng/ml
PTX (all results are summarized in Additional file 2:
Figure S3). To establish the dose of SR4987PTX cells to
inject in vivo, we co-cultured SR4987PTX and B16 cells at
different ratio using trans-well inserts. We found that the
optimal dose/ratio of SR4987PTX/B16 was around 1/5 that
inhibited B16 melanoma proliferation of 70 % (Additional
file 2: Figure S4).
SR4987 and SR4987PTX were also able to bind
B16 cells by a rosette formation assay. The ultra-
structure analysis of the rosette showed the presence
of junctional-like structure and even a gap-like junc-
tion between SR4987 and B16 cells. At TEM, the po-
tent cytotoxic activity of SR4987PTX on B16 cells
was very evident; most of the B16 cells bound to
SR4987PTX were apoptotic and necrotic (Additional file 2:
Figure S5).
In vivo systemic administration of SR4987 PTX suppresses
B16 lung metastasis in syngeneic mice
B16 melanoma cells were injected into the tail vein
of syngeneic C57Bl6 mice at the dose of 2.5x105/
0.2 ml. On day 5 after tumor injection, mice were
divided in 5 groups receiving respectively: saline
(controls), PTX 10 mg/Kg, SR4987 at 1×105/0.2 ml,
SR4987PTX at 1×105 /0.2 ml and at 5×104/0.2 ml.
Treatments were repeated on day 10 and 15 for a
total of three administrations and all mice were sacrificed
on day 21. As summarized in Table 1 (section A),
SR4987PTX treatments produced a potent lung metastasis
suppression at both doses used (around 90 % inhib-
ition; p < 0.001 vs control). The number of B16 lung
nodules was not affected by SR4987, while PTX treat-
ments, given at the maximum tolerated dose (MTD)
Table 1 SR4987PTX injected i.v. suppress B16 lung metastasis
Section A
Groups days of
treatments
Median number
of lung metastasis
(interval)
% of Metastasis
inhibition
Controls (saline) 0 37 (12-60) -
PTX (10 mg/Kg) 5,10,15 11 (11-15)* 70.3
SR4987 (105) 5,10,15 40 (16-51) 0
SR4987PTX (105) 5,10,15 5 (2-9)**,° 86.5
SR4987PTX (5×104) 5,10,15 3 (2-4)**,° 91.8°
Section B
Controls (saline) 0 29 (12-32) -
PTX (10 mg/Kg) 5,10,15 10 (9-11)* 65
SR4987PTX(5×104) 5,10,15 3 (2-4)**,° 90°
Legend. On day 0, C57Bl6 mice were injected i.v. with 2.5×105/0.2 ml B16
melanoma cells On day 5, 10 and 15 after B16 injection, mice were treated i.v.
with saline (controls), PTX (10 mg/Kg), SR4987(105/0.2 ml) and SR4987PTX at
105 and 5×104/0.2 ml respectively. On day 21 after tumor cells injection, mice
were sacrificed and lung nodules counted under a dissecting stereomicroscopy.
Numbers in the table are the median number and the range of metastases
determined for each group of mice (12) and are the media of three different
experiments. *p < 0.05; **p <0.01 vs controls; ° p < 0.05 vs PTX treated mice
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of 10 mg/kg, reduced metastasis (p < 0.01 vs control)
but significantly less than SR4987PTX (p < 0.05). It is
important to outline that the total dose of PTX given
free was around 2,000 fold higher than mice that re-
ceived PTX delivered by cells, thus highlighting the
remarkable efficacy of SR4987PTX treatment. Repeat-
ing the experiment using SR4987PTX only at the low
dose of 5×104 we confirmed the potent anti-metastatic
activity (Table 1 section B). Besides the quantification
of lung metastasis performed under dissecting stereo-
microscopy (Additional file 2: Figure S6), histology of
the lungs confirmed that in control and in SR4987
treated mice several metastasis were present, whereas
in mice treated with SR4987PTX, rare metastasis were
seen (Fig. 1a). A similar picture was observed in mice
treated with PTX alone (Fig. 1a). However, analyzing
the lung parenchyma by Fontana-Masson staining,
that lead to a better detection of micrometastasis, we
observed that micrometastasis were practically absent
in SR4987PTX treated mice. On the contrary in PTX
treated mice some residual B16 micrometastasis were
present (Fig. 1b). We conclude that three injection of PTX
at MTD (10 mg/kg) was significant less effective than
SR4978PTX that even had a superior activity in eliminat-
ing also micrometastasis.
B16-CM and TNFα improve adhesion of SR4987PTX to
microvascular endothelium and to stromal cells of the
lung
In order to understand the mechanism of SR4987PTX
homing to metastatic lung, we started to evaluate
whether B16 cells could affect the capacity of SR4987PTX
to interact to lung-derived microvascular endothelial cells
(L-MECs) and/or to mouse lung-derived stromal cells
(mL-.StCs). To this end, adhesion experiments were per-
formed by seeding SR4987 and SR4987PTX on L-MECs
and on mL-StCs monolayer. As shown in Fig. 2, both
SR4987 and SR4987PTX had a poor capacity to adhere on
L-MECs and mL-StCs, in contrast they adhere rapidly on
L-MECs (Fig. 2a and b) and mL-StCs (Fig. 2c and d)
after stimulation either with B16-CM or TNFα, an in-
flammatory cytokine that is known to increase adhe-
sion molecules expression on both endothelium and
StCs [30, 31]; to note that the combination B16-CM+
TNFα significantly enhanced adhesion of SR4987 and
SR4987PTX on both L-MECs and mL-StCs.
Fig. 1 Histological examination of the lungs showing the potent anti-metastatic activity of SR4987PTX treatment. a HE staining shows the
presence of several B16 lung nodules (black arrows) in control mice (CTRL) and in SR4987 treated mice. Some metastasis are present in
mice treated with a very high dose of PTX (10 mg/kg), while mice treated with SR4987PTX appear without metastatic nodules. b
Fontana-Masson staining shows the presence of lung micrometastasis (red arrows) in PTX and their absence in SR4987PTX treated mice
(boxes 600x magnifications)
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Priming of mL-StCs with B16-CM alone or combined with
TNFα stimulate SR4987PTX chemotaxis that is mediated
by SDF-1/CXCR4/CXCR7 axis
We next performed chemotaxis experiments by using
trans-well insert. Under control medium (CTRL) condi-
tion, we found that SR4987PTX had a significant lower
spontaneous motility than SR4987. Surprisingly, the
addition of B16-CM, as chemotactic stimulus, did not
substantially improve basic migration of both SR4987 and
SR4987PTX (Additional file 2: Figure S7). We then tested
the CM recovered from culture of mL-StCs (mL-StCs-CM)
and again no significant increase of migration was ob-
served. However, when mL-StCs were primed first with
B16-CM (mL-StCs-B16-CM), TNFα (mL-StCs-TNFα-
CM) or their combination (mL-StCs-TNFα-B16-CM),
a potent induction of both SR4987 and SR4987PTX
migration was noted (Fig. 3). The oriented movement of
SR4987PTX was highest in the presence of mL-StCs-
TNFα-B16-CM (around 10 fold higher than control) but
either addition of mL-StCs-B16-CM and to lesser extent
mL-StCs-TNFα-CM were effective (6 and 3 fold the
CTRL respectively) (Fig. 3a). Untreated SR4987 be-
haved similarly to SR4987PTX (Fig. 3b). Additionally,
we also found that SDF-1, a cytokine known to be a
chemoattractant for MSCs [32] was effective to stimu-
late both SR4987PTX and SR4987 at 20 and 10 ng/ml
respectively (Fig. 3a and b).
Since the efficacy of SDF-1 and because SR4987
cells expressed a high level of CXCR4 (90 %) and, to
minor extent, CXCR7 (20 %) SDF-1 receptors [33]
Fig. 2 Adhesion of SR4987 and SR4987PTX to L-MECs and mL-StCs improved by B16-CM, TNFα and their association. a quantification of SR4987 and
SR4987PTX that adhere to L-MECs monolayers not treated (CTRL) or treated with TNFα, B16-CM and TNFα + B16-CM respectively. b photographs (20x),
showing the SR4987PTX cells (white arrows) that adhere on L-MEC monolayers. c quantification of SR4987 and SR4987PTX that adhere to mL-StCs
monolayers. d photographs (20x) showing the adherent SR4987PTX cells on mL-StCs monolayer. The bars in the figure are the mean ± SD of cells
counted with a calibrated eyepiece in 15 different fields at 40X magnification. Each test was run in quadruplicate. (*P < 0.05;**P < 0.01 vs CTRL)
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(Additional file 2: Figure S7), we then verified if SDF-
1 could be a mediator of SR4987 and SR4987PTX
chemotaxis in the metastatic lung. We first analyzed
in vitro the capacity of B16 and mL-StCs to release
SDF-1. We found that B16 cells and mL-StCs did not
release a significant amount of SDF-1 in the CM (Fig. 3c).
However, when mL-StCs were primed with B16-CM alone
or combined with TNFα the concentration of SDF-1 in
the medium was significantly increased (Fig. 3c). These re-
sults were also confirmed by analyzing the expression of
SDF-1 by PCR performed on mL-StCs under the different
treatments conditions (Fig. 3d).
Migration experiments of SR4987PTX and SR4987 were
repeated by adding anti-SDF-1 antibodies or in the pres-
ence of AMD3100 a molecule able to bind specifically the
SDF-1 receptors CXCR4 and CXCR7 [34]. Anti-SDF-1
antibodies and AMD3100 were both able to significantly
reduce chemotaxis (Fig. 3e and f).
Increment of SDF-1 expression and presence of SDF-1+
cells in the lung of mice bearing B16 melanoma
metastasis
Subsequently, by using SDF-1 antibodies, we investi-
gated the expression of SDF-1 and the localization
of SDF-1+ cells in normal and in B16 metastatic
lungs (Fig. 4). In summary SDF-1 expression and
the SDF-1+ cells were practically absent in normal
lung (Fig. 4a) but highly expressed in mice with
metastasis (Fig. 4b). SDF-1+ cells were particularly
localized in the lung stroma near or at periphery
of metastasis, but absent inside metastatic nodules
(Fig. 4c and d). Interestingly, the observation at higher
magnification of the periphery of metastasis, revealed
that SFD-1 staining was present in some cells but
mostly widespread among cancer cells; while a diffuse
staining along the extreme periphery of the metastases
was noted (Fig. 4e and f).
Fig. 3 Chemotaxis of SR4987 and SR4987PTX induced by mL-StCs-CM upon priming with B16-CM or B16-CM+ TNFα mediated by SDF-1/CXCR4/CXCR7
axis. In (a) SR4987PTX and (b) SR4987 cells migration. Bars are the mean ± SD of three independent experiments. Note the chemotactic activity of
mL-StCs-B16-CM and mL-StCs-TNFα-B16-CM on both SR4987PTX and SR4987 (*P< 0.05;**P< 0.01 versus CTRL). B16-CM and mL-StCs-CM are not effective
while SDF-1 induces SR4987PTX and SR4987 chemotaxis. In (c) SDF-1 secreted by the B16 melanoma cells and by mL-StCs under different stimuli. Bars
are the mean value ± SD of SDF-1 detected in the CMs normalized for the same number of cells (106). In (d) the analysis of SDF-1 at mRNA level in B16
and mLStCs under different culture conditions. Bars ± SD are the relative gene expression calculated by a comparative method (2-ΔΔCt) using GAPDH as
an housekeeping gene. In (e) SR4987PTX and (f) SR4987 cells migration in the presence of anti-SDF-1 (1 μg/ml) or after cells priming with AMD3100
(1 μM). Note that both anti-SDF-1 and AMD3100 significantly reduce chemiotaxis (° < 0.05 versus no anti-SDF-1 addition; **p < 0.01 versus no
AMD3100 treatment)
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SR4987PTX cells localize preferentially in the vessels
nearby metastatic nodule
To detect the presence and to roughly quantify the num-
ber of SR4987PTX in the metastatic lung, anti-Sca-1
antibodies were used (Fig. 5). We found that mice
treated with either SR4987 and SR4987PTX had al-
most 5-6 fold Sca-1+ cells/mm2 higher than control
and 3 fold of PTX treated mice (Fig. 5a). The pres-
ence of few Sca-1+ cells in control and PTX treated
mice suggested a little endogenous mobilization of
MSCs from BM (Fig. 5b and c). However, in these
mice, Sca-1+ cells were not seen nearby metastasis
(Fig. 5d and e). In mice treated with SR4987, we
found several Sca-1+ cells in lung parenchyma (Fig. 5f),
but even within metastases (Fig. 5g). Finally in mice
treated with SR4987PTX a significant presence of Sca-1+
cells in close proximity of microvessels (Fig. 5h) and
nearby metastatic nodule were observed (Fig. 5i). Substan-
tially, Sca-1+ cells were detected near the microvessels
where most of the metastasis were localized (Fig. 5j). By a
more accurate observation, we discovered that some Sca-
1+ cells were even present in the lumen of microvessels
infiltrating metastatic nodule (Fig. 5i and m), demonstrat-
ing that SR4987PTX cells could reach metastasis through
the hematic route and that they may strongly affect cancer
cells growth even if they do not cross the vessels wall.
Discussion
MSCs may represent a novel therapeutic tool for fighting
cancer [1]. MSCs can be engineered to produce and de-
livery anti-cancer molecules [3–6, 35, 36] or, as our
group have recently demonstrated, MSCs can become
Dr-MCs upon priming with anti-cancer drug like PTX,
acquiring strong anti-cancer activity both and in vivo
[15, 16]. Paclitaxel is an important molecule active on
many solid tumors including melanoma [37] and also
with anti-angiogenic activity. PTX priming of MSCs in-
duces mitotic arrest of the cells without affecting their
viability and allowing to the uptake/release mechanism
to properly works. These features have been verified
also for Vincristine and drugs with other mechanism
of action as Gemcitabine and Doxorubicin. In any
case, regardless the kind of manipulation used, it is
necessary that MSCs maintain their homing ability
because is crucial to localize their cytotoxic cargo in
the tumor. At this regard, the therapeutic localization
of MSCs in organs such as lung is certainly facilitated
by i.v. administration [10, 11].
To expand our previous work, we here investigated
whether the i.v. injection of Dr-MCs loaded with PTX
may inhibit the formation of lung metastases, induced in
C57Bl6 mice upon i.v. injection of syngeneic B16 melan-
oma cells. To exclude any immunological interference
Fig. 4 SDF-1 expression and presence of SDF-1+ cells in the lung of mice bearing B16-melanoma metastasis. a-f Immunostaining for SDF-1 of
normal and metastatic lung. In (a) normal lung parenchyma shows no staining for SDF-1 at lower (200x left panel) and at higher magnification
(600x right panel). In (b) metastatic lung parenchyma shows an intense SDF-1 staining at both magnifications (200x and 600x). In (c,d) the
metastatic lung shows the presence of SDF-1+ cells (white arrows) in the parenchyma near or at periphery of metastasis (m). In (e,f) high
magnification of a lung metastasis (m) showing the presence of SFD-1 + cells (white arrows) and a diffuse SDF-1 staining (red arrows) along the
entire border of the metastasis
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by the host, as Dr-MCs, we used the SR4987 cells, a
BM-derived MSCs line syngeneic to C57Bl6 mice [23]
and able to uptake and release PTX and to kill cancer
cells [15, 16].
We found that 5×104 SR4987PTX cells injected i.v.
three times, starting from day 5 after tumor injection,
were sufficient to produce up to 90 % of lung metastasis
inhibition; an effect that was even superior of those ob-
tained with PTX given at the MTD of 10 mg/Kg. Be-
cause SR4987 may incorporate at maximum around
2.5 pg/cell of PTX [15], the dose of PTX that mice re-
ceived through the cells was about 2000 times less than
the groups treated with PTX. Thus, we conclude that
the delivery of the drug through the cells has a signifi-
cantly higher therapeutic index than the PTX given
through the standard therapy. Previous reports have
shown the efficacy of engineered MSCs delivering anti-
cancer molecules, or MSCs per se, to inhibit lung metas-
tases upon i.v. administration [5, 6, 38–40]. Our results
expand these observations, and demonstrate for the first
time that syngeneic MSCs loaded with PTX given sys-
temically in mice bearing lung metastasis, have a potent
therapeutic effect.
The capacity of SR4987PTX to home malignant lung
nodules was investigated both in vitro and in vivo. In
summary our results indicate that SR4987PTX once
injected i.v., are able to reach metastatic lung nodules
through a complex mechanism involving mainly the
chemokine SDF-1/CXCL12 and its receptors CXCR4/
CXCR7. These data confirm previous reports showing
Fig. 5 Sca-1+ cells in lung parenchyma of SR4987PTX injected mice localize in vessels nearby metastatic nodule. Anti-Sca-1 antibodies
were used to investigate the capacity of SR4987 and SR4987PTX to home lung B16 nodules. a quantification of Sca-1 + cells in the lungs.
Bars are the mean ± SD of three mice and are the number of Sca-1+cells/mm2 counted at 400X (**p < 0.01 vs CTRL or PTX treated mice).
b,c,f,h Immunostaining for Sca-1 of metastatic lung parenchyma and (d,e,g,i) metastasis (m) area. Very few Sca-1+ cells (white arrows)
are present in the lung of control and PTX treated mice in both parenchyma (b,c) and metastasis area (d,e). Mice treated either with
SR4987 (f,g) and SR4987PTX (h,i) show many Sca-1+ cells in the lung parenchyma near the vessels (V) and at the periphery of metastatic
nodules (200x magnifications). (J) Fontana-Masson staining showing B16 metastasis nearby (top left panel) or surrounding a lung
microvessel (bottom right panel). In (L,M) Sca-1+ cells (black arrows) are attached to endothelium of tumor infiltrating microvessels
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the importance of SDF-1/CXCR4/CXCR7 axis in the
homing of MSCs to cancer environment [41–44]. How-
ever, besides this, our study highlights a new undiscov-
ered mechanism of MSCs homing in metastatic lung
that is not mediated directly by B16 cells but through
the implication of lung StCs. Indeed, our in vitro data
show that B16-CM neither stimulates chemotaxis of
both SR4987 and SR4987PTX nor contains significant
amount of SDF-1. In contrast, CM derived from mL-
StCs primed with B16-CM, secretes SDF-1 and stimu-
lates chemotaxis of SR4987PTX. Further, the in vivo
analysis of the SDF-1+ cells localization in metastatic
lung, reveals that most of the SDF-1+ cells are not
present inside metastasis but are localized in the lung
stroma or at the extreme periphery of metastatic nod-
ules. We therefore conclude that SR4987PTX, once
arrested in the lung, migrate toward B16 metastasis by
an “indirect mechanism” mediated by SDF-1 secreted by
StCs of the lung under the influence of factors released
by B16 cancer cells. In this contest, TNFα seems to play
an important role as enhancer of the B16 cancer cells
activity.
Our results thus highlight the importance of StCs sur-
rounding the metastatic nodule that seem to behave like
tumor stromal cells in favoring the progression of primary
cancer [45–47]. Whether this StCs-mediated attraction of
MSCs is occurring in other metastatic organs besides lung,
remains to be established. The finding that lung contains
specific resident MSCs that differ from those from BM
[48], may suggest an organ-specific activity of lung MSCs
in controlling local tissue diseases [49, 50].
Finally, the in vivo search of SR4987PTX in metastatic
lung demonstrated the presence of many Sca-1+ cells in
parenchyma and even inside metastatic nodules. The few
Sca-1+ cells present in the lung of control and PTX
treated mice suggested a modest endogenous mobilization
of MSCs from BM, at least at the time of mice sacrifice.
Notably, we observed that Sca-1+ cells in mice injected
with SR4987PTX were mostly detected nearby metastases
or even attached to endothelium of the microvessels infil-
trating metastatic foci; thus very close to cancer cells. To
note that the vicinity of Dr-MCs to cancer cells is an im-
portant condition to ensure the efficacy of their toxic
cargo (PTX) [15, 16]. In our opinion this result could ex-
plain the potent anti-metastatic effect obtained even when
mice were treated with a lower dose of SR4987PTX.
Conclusions
Tumor recruits MSCs from host BM to form its stroma
[41, 42, 51] a mechanism probably essential for tumor
progression [45–48]. We can use this cancer property to
fight it by administrating exogenous MSCs that can
work as Trojan horses carrying in the tumor anticancer
molecules [1]. Although the presence of some conflicting
data [52, 53], in general preclinical studies indicate that
MSCs loaded with anti-cancer molecules could be very
effective to inhibit primary and metastatic cancer growth
[3–6]. The results shown here clearly demonstrated that
our approach to upload anticancer drug, such as PTX,
on MSCs lead them to become strongly cytotoxic against
cancer and, importantly, without altering their home
properties. Actually, a cure for lung metastasis in
humans is mostly unlikely and we do not know whether
a therapy combining engineered MSCs and Dr-MCs
may work synergistically. However, we think that our ap-
proach using Dr-MCs loaded with PTX may represent a
new valid and additive therapeutic tool to fight lung me-
tastases and, perhaps, primary lung cancers in human.
Additional files
Additional file 1: Supplementary materials and methods. (DOC 45 kb)
Additional file 2: Figure S1. SR4987GFP and SR4987GFP-PTX arrest in
the lung of mice upon i.v. administration. Mice were sacrificed at 6 h,
24 h and 48 h after treatments with cells. Panel (A) shows photos taken
under fluorescent microscopy immediately upon enzymatic lung tissue
disruption, showing the presence of several fluorescent cells until 48 h
after their injection. Not significant difference were noted between mice
treated with SR4987GFP and SR4987GFP-PTX (10x magnification). Panel
(B) shows photos of SR4987GFP and SR4987GFP-PTX cultured for 2 and
7 days upon isolation from mice, indicating that cells maintain their
viability (20x magnification). Figure S2. Sca-1 is highly expressed on
SR4987 and can be used for their detection in the mice lung. In (A) FC
analysis showing the high positivity of the SR4987 for Sca-1. In (B),
Immunostaining for anti-Sca-1 of lungs derived from mice treated i.v.
with saline , 106 SR4987 and 106 SR4987PTX cells and sacrificed 24 h after
treatments. Pictures show the high presence of Sca-1+ cells
(black arrows) in the parenchyma and in the lumen of lung vessels in
mice treated with both SR4987 and SR4987PTX. Only, very few Sca-1+
cells were detected in control mice (CTRL) (photo 20x, in the box 40x
magnifications). Figure S3. Sensibility of SR4987 to PTX and efficacy of
SR4987PTX-CM to inhibit B16 proliferation. In (A) the proliferation of
SR4987 in the presence of increasing concentration of PTX. The IC50 of
PTX was around 34 ng/ml. In (B) is shown that viability of SR4987 is not
affected by PTX even at concentration up 5000 ng/ml. In (C) is shown
the growth inhibition of Molt-4 tumor cells in the presence of decreasing
dilution of SR4987PTX-CM confirming that SR4987PTX release significant
amount of PTX in the CM. In (D) the inhibition of proliferation of B16 cells
in the presence of increasing concentration of PTX. The IC50 is 7.18 ±
4.99 ng/ml. In (E) is shown the dose dependent efficacy of SR4987PTX-CM
to inhibit B16 cells proliferation with an IC50 DIL of around 1/10. Figure S4.
Co-culture of SR4987 and SR4987PTX with B16 cells using transwell insert.
B16 cells seeded on the top of membrane (0.4 um pore size) insert were
co-cultured with different dose of SR4987 and SR4987PTX seeded on the
bottom well and cultured for 5 days. The Figure shows that SR4987PTX at
1:5 ratio was able to strongly inhibit B16 proliferation as visualized by crystal
violet staining of B16 in the transwell line (A) and on the membrane line (B).
In line (C), photos of cultured B16 cells not stained upon co-culture or not
with SR4987 and SR4987PTX (20x magnifications). Figure S5. Rosette formed
by B16 + SR4987 and B16 + SR4987PTX and their ultrastructural analysis by
TEM. In (A) and (B) rosette formed by SR4987GFP + B16 photographed
under light and fluorescence microscopy respectively. (C-F) four different
panels at TEM showing the interactions between untreated SR4987GFP and
B16 cells. Note that B16 cells bound SR4987GFP appear healthy (C);
the presence of area of contact between B16 and SR4987 is evident;
junctional-like structure and a gap-like junction (D,E) and even nanotubule
structure (F) are seen (white arrows). In (G) and (H) rosette formed by
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SR4987GFP-PTX + B16. Note that most of B16 cells appeared damaged and
necrotic under light (G) and fluorescence (H) microscopy observation. In (I-L)
four different panels at TEM showing the interaction between SR4987GFP-PTX
and B16. The B16 cells bound to SR4987GFP-PTX show varying degrees
of degeneration, some cells seemed even emptied of their cytoplasm
(I) and, similarly to untreated SR4987, area of contact (white arrows) can
be observed (J,K). In (L) a microvescicole that arise from SR4987PTX is
photographed. Figure S6. Metastasis in the lung of control mice and
after treatment with PTX, SR4987 and SR4987PTX. On day 21 after B16
cells injection, mice were euthanized, lungs removed and fixed in Bouin’s
solution. In the figure photos of the lungs, taken under a dissecting
stereomicroscope. Note the presence of several melanoma lung nodules
(black arrows) in control and SR4987 treated mice. In contrast, at both
dosage of SR4987PTX injected, the lung nodules are very few and are
significantly less than those detected in PTX treated mice. Figure S7.
Chemiotaxis of SR4987 and SR4987PTX in response to B16-CM and
expression of the SDF-1 receptors CXCR4 and CXCR7. In (A) migration
of SR4987PTX and SR4987 placed on the top of transwell membrane
insert and stimulated by different dilution of B16-CM. No significant
chemotaxis activity of both SR4987 and SR4987PTX is stimulated by
B16-CM at every dilutions tested. Note that the basal migration of
SR4987PTX is around three fold lower than untreated SR4987 (* p< 0.05). In
(B) is showed FC analysis of SR4987 for the expression of the SDF-1 receptors
CXCR4 and CXCR7, indicating the high positivity of the cells particularly for
CXCR4 (>90 %), CXCR7 is less expressed (18 %). (DOC 26 kb)
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